
Trevena
Clinical stage biopharmaceutical company discovering and developing g-protein coupled receptors (gpcr) biased ligands.
Market cap
$959k
Enterprise value
$25m
Share price
$1.05 TRVN
Authorizing premium user...
Clinical stage biopharmaceutical company discovering and developing g-protein coupled receptors (gpcr) biased ligands.